Question · Q3 2025
Andrew Boone asked about the financial profile of METHODIQ, specifically regarding potential differences in AOVs and margin profiles over the next three years. He also sought clarification on the expected contribution of ODDITY Labs' proprietary molecules, including the eight products planned for 2026, and the long-term path for these innovations.
Answer
Lindsay Drucker Mann, CFO of ODDITY, stated that METHODIQ is expected to align with Il Makiage and SpoiledChild's long-term financial profile, targeting 20% revenue growth and 20% adjusted EBITDA margins. She noted that prescription products within METHODIQ might initially have lower gross margins due to third-party costs but anticipate strong repeat business. Regarding ODDITY Labs, she explained the strategic pivot to higher-efficacy molecules, confirming eight products with Labs' molecules for 2026 (four for METHODIQ, four for other brands), with more in the pipeline. Oran Holtzman, Co-founder and CEO of ODDITY, emphasized the significant progress and strength of Labs' development.
Ask follow-up questions
Fintool can predict
ODD's earnings beat/miss a week before the call